Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 1/20 | 0.72 |
| ▸ | EIF4E | P06730 | 6/20 | 0.64 |
| ▸ | NT5C3B | Q969T7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438538 | 0.98 | DCPS (0.72) | DCPSEIF4ENT5C3B | |
| SCHEMBL29390254 | 0.94 | DCPS (0.70) | DCPSEIF4ENT5C3B | |
| SCHEMBL31122854 | 0.92 | DCPS (0.70) | DCPSEIF4ENT5C3B | |
| SCHEMBL29824509 | 0.90 | DCPS (0.72) | DCPSEIF4ENT5C3B | |
| SCHEMBL29689260 | 0.85 | DCPS (0.92) | DCPS | |
| SCHEMBL29361534 | 0.85 | DCPS (0.95) | DCPSEIF4E | |
| SCHEMBL29448235 | 0.76 | DCPS (0.76) | DCPSEIF4E | |
| SCHEMBL2223109 | 0.75 | TGM2 (0.57) | DCPS | |
| SCHEMBL4317980 | 0.72 | DCPS (0.66) | DCPS | |
| SCHEMBL18769111 | 0.70 | TGM2 (0.59) | DCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240181-A1 | NEUROPROTECTIVE MOLECULES AND METHODS OF TREATING NEUROLOGICAL DISORDERS AND INDUCING STRESS GRANULES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11866754-B2 | Trinucleotide mRNA cap analogs | MODERNATX, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4086269-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | ModernaTX, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11439656-B2 | Pharmaceutical compounds and uses thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220151976-A1 | TARGETING LASP1, EIF4A1, EIF4B AND CXC4 WITH MODULATORS AND COMBINATIONS THEREOF FOR CANCER THERAPY | THE UNIVERSITY OF TOLEDO (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3362461-B1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX INC (US) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151976-A1 | TARGETING LASP1, EIF4A1, EIF4B AND CXC4 WITH MODULATORS AND COMBINATIONS THEREOF FOR CANCER THERAPY | LASP1, CXCL12, LAS1L | DCPS 4361/4885EIF4E 107/4885NT5C3B 4192/4885 |
| US-11439656-B2 | Pharmaceutical compounds and uses thereof | TP53, CAPNS1, TP53BP1 | DCPS 2122/4885EIF4E 218/4885NT5C3B 2733/4885 |
| US-11866754-B2 | Trinucleotide mRNA cap analogs | RNGTT, RNMT, CPSF7 | DCPS 262/4885EIF4E 72/4885NT5C3B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.